Covid-19 Coronavirus vaccines types and their efficiency Australia

Covid-19 Coronavirus vaccines types and their efficiency Australia

Australia has entered into 5 separate agreements for the supply of COVID-19 vaccines if they are proved to be safe and effective. There has been much news of late concerning COVID-19 vaccine progress from the two big American pharmacy firms, Pfizer and Moderna and British Astra Zeneca / University of Oxford. But no information from mainstream media about Chinese and Russian COVID-19 vaccines that were first available at the market.

Covid-19 Coronavirus vaccines types and their efficiency Australia more details

The Australian Government is currently consulting with the states and territories, key medical experts and industry peak bodies on the framework for the initial roll-out of the COVID-19 vaccination program in early 2021.
Key vaccination sites will initially include GPs, GP respiratory clinics, state and territory vaccination sites and workplaces such as aged care facilities.
Australia has a world-class vaccination program with world-leading vaccination rates. The COVID-19 vaccine will not be mandatory and individuals will maintain the option to choose not to vaccinate. The vaccine will be available for free to those who choose to be vaccinated., Greg Hunt Health Minister said.

Available Covid-19 Coronaviruses Vaccines data

Covid-19 Coronavirus vaccines types details

Chinese vaccine Sinopharm informations

Two vaccine candidates developed by Sinopharm subsidiary China National Biotec Group Co. have been approved for emergency use since July for medical workers and other limited groups of people who face a high risk of infection.
The vaccines, which use an inactivated virus unable to replicate in human cells to trigger immune responses, require two doses, clinical trial registration data showed.
Nearly one million people have taken the vaccines in the emergency use program, and no serious adverse reaction has been reported, CNBG said last Wednesday in an article posted on its official WeChat account.
On November 17, Liu Jingzhen, chairman of Sinopharm, said that the vaccine candidates have been under Phase-3 clinical trials in 10 countries including the UAE, Bahrain, Egypt, Jordan, Peru, and Argentina, with nearly 60,000 people inoculated. Blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, showing excellent results.

Already, numerous countries have ordered vast amounts of Chinese vaccines to diversify their options from western dependency and overcome climate obstacles, and for their competitive affordability.
Many are being donated via a subsidized program, COVAX via the World Health Organization. Malaysia has signed up to become the first recipient of such under the WHO COVAX program and, of course, there will be more. Countries that have ordered Chinese manufactured vaccines include Indonesia, Sao Paulo province in Brazil, Mexico, Malaysia – donation as mention COVAX WHO, Turkey and the Philippines. The scope of countries to receive donations from Beijing is also likely to be ramped up as China intensifies its multilateral cooperation to fight the COVID-19.
Zheng Zhongwei, the Chinese official in charge of vaccine development, has said that the country plans to have 600 million doses of vaccine ready by end of this year.

China impressed with its ability to carry out large-scale operations since the beginning of the pandemic, including building new hospitals and testing millions of people within a number of days.

Russian vaccine Sputnik V – Gamaleya informations

Russia became the first country in the world to register a vaccine for Covid-19. Details were subsequently published in The Lancet medical journal, which showed it was able to induce an immune response in healthy volunteers. Concerns were expressed, however, by some international scientists and commentators over the urgency with which the vaccine was brought forward.
The Gamaleya team was able to develop and test the vaccine quickly thanks to what they call – a well-tested technology platform with substantiated long-term safety. This approach, using adenoviruses, has already led to three vaccines for Ebola, as well as two new cancer drugs currently in use. Utilizing this platform is also thought to play a role in how swiftly and cheaply the jab can be manufactured and, therefore, its lower price.

While countries across Europe, Asia and the Americas have worked feverishly to secure future supplies of vaccines, often buying into multiple companies order books to hedge their bets, there have been fears that poorer nations could be left out. World leaders used the first day of the G20 summit to pledge to “spare no effort” to ensure people across the globe have equitable access to vaccines, tests and anti-coronavirus drugs, according to a communique shared with the media.

Prices of Covid-19 Vaccines

Russia Sputnik V – Gamaleya $10 for both jabs
A spokesman for the Russian Direct Investment Fund (RDIF), which financed the formula developed by Moscow’s Gamaleya Center, said their pricing structure will be formally announced next week. It had previously been indicated that the export price would be around $10 for both jabs.
China Sinopharm/ SinoVac /CanSino should be about same price like Sputnik V
Many are being donated via a subsidized program, COVAX via the World Health Organization.

Prices of Covid-19 vaccines from others
Pfizer that filed for FDA US approval of its formula on Saturday, said earlier that a dose of its product will carry a $19.50 price tag. Moderna thought to be close to signing a deal for a comprehensive rollout in the European Union, announced this week that it will charge between $25-37. As two doses of the vaccine are required per person, spaced out over several weeks, the overall cost will be doubled. $39 and $50-74 USD

Storage of the Vaccines and temperatures
The main issue with the vaccines from companies such as Moderna, Pfizer/BioNTech is the storage and transport temperatures -20 and -70 degrees of Celsius. That will not be probably the choice of many countries.

95% effective why not 100%?

If that’s true 95% of vaccine efficiency is the great result comparing to the seasonal flu jabs with an efficiency of around 65%. There are not known the side effects or long term side effects of the vaccines at the moment.
Important dosage of Covid-19 Coronavirus vaccine
Why it is so important? Let’s explain it as simple as possible. The immune system can reject the vaccine, which is built around a common cold virus if it is given in too big an initial dose!!!
Or a low then high shot may be a better mimic of a coronavirus infection and lead to a better immune response. Precise dosage is important, it can change the efficiency of the vaccine, but it depends on the methodology used to manufacture the vaccine. The response of the human body to the vaccine should vary.
Read bellow AstraZeneca – different concentration/dosage caused the first disappointment of low efficiency of the Covid-19 vaccines.


AstraZeneca reveals dosing mistake in coronavirus Covid-19

AstraZeneca and the University of Oxford’s coronavirus vaccine’s high efficacy may have been in part due to a dosing error.
In the press release on the vaccine’s efficacy released on Monday, the vaccine candidate had a higher efficacy – up to 90% – in the group that received a half dose and then a full dose. A spokesperson for the University of Oxford told Euronews that – as a result of a difference in the manufacturing process” the phase I trial method was “shown to over-estimate the dose on the new batches of vaccine resulting in a half dose of the vaccine being administered as the first dose.
After discussing it with the regulator, the two different concentrations were tested in phase III trials.
Need to be further rewied

Based on the official source of Australian government they never considered Russian or Chinese made Covid-19 vaccines.

When will I get a vaccine?

Official press release of Greg Hunt Health minister of Australia – Australia secures a further 50 million doses of COVID-19 Coronavirus vaccine.
Two more COVID-19 vaccines have been secured for the Australian population under new agreements, bringing the Australian Government’s COVID-19 vaccine investment to more than $3.2 billion.
Under the agreements, Novavax will supply 40 million vaccine doses and Pfizer/BioNTech will provide 10 million vaccine doses, should the vaccines be proven safe and effective.
Prime Minister Scott Morrison said the Government’s COVID-19 Vaccine and Treatment Strategy had now secured access to four COVID-19 vaccines and over 134 million doses.
“By securing multiple COVID-19 vaccines we are giving Australians the best shot at early access to a vaccine, should trials prove successful,” the Prime Minister said.

Australian Government agreement for Covid-19 vaccines and research official source

– invested $363 million to support research and development, to contribute to the global effort to find successful vaccines and treatments to stop the spread of COVID-19.
– invested more than $3.3 billion through these 5 agreements, which will strengthen Australia’s position to access safe and effective vaccines when they become available.

The University of Oxford vaccine is one of the most progressed vaccines in development globally for Coronavirus (COVID-19). If it is proven to be safe and effective and is approved for use, it will be available in Australia from early 2021, as part of the Australian Government’s COVID-19 Vaccine and Treatment Strategy. In Australia, the vaccine would be manufactured by Australian-headquartered multinational biopharmaceutical company CSL in partnership with the developer, international pharmaceutical company AstraZeneca. The Oxford vaccine is one of nine vaccines supported by the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership to accelerate vaccine development.

Testing process
All vaccines must pass different stages of research trials to prove they are safe and effective. The CSIRO partnered with the CEPI to test the vaccine in pre-clinical (animal) trials in Australia. The Oxford vaccine has completed combined Phase 1 and 2 clinical trials, where it was tested in a small number of volunteers to show that it is safe. Trial results showed a strong antibody and T-cell response in participants. Larger combined Phase 2 and 3 clinical trials are now underway in the United Kingdom, United States, Brazil and South Africa.

Doses for Australia
Before the Oxford COVID-19 vaccine is approved for use in Australia it must pass the Therapeutic Goods Administration’s (TGA) rigorous assessment and approval processes. This includes the assessment of its safety, quality and effectiveness. The TGA is actively monitoring COVID-19 vaccine development that is occurring both in Australia and around the world. In October 2020, the TGA granted a provisional determination to AstraZeneca for this vaccine candidate. This means that it is now eligible to apply for provisional registration on the Australian Register of Therapeutic Goods. If the Oxford vaccine is successful: • 3.8 million doses will be delivered to Australia in early 2021 • 30 million doses will be manufactured in Australia between from early 2021 in monthly batches through to September 2021 in monthly batches. CSL will manufacture these doses on behalf of AstraZeneca.


0 Comments Be First to Comment

Leave a Reply

Your email address will not be published.

You may have missed
Denmark suspends use of AstraZeneca COVID-19 vaccine